Robert S. Langer, "Looking Forward"
-
Upload
the-petrie-flom-center-for-health-law-policy-biotechnology-and-bioethics -
Category
Healthcare
-
view
7 -
download
1
Transcript of Robert S. Langer, "Looking Forward"
Petrie Flom: Looking Forward February 7, 2017
Panelist: Bob Langer
Biologics present unique delivery challenges
• Small molecules vs biologics • Unique challenges for biologics
• Thick solution requires large volume doses • Inherently less stable than small molecules
• Approaches to improve dosing
• Drug-based • Change the drug itself, making a new drug
• Delivery-based • Oral with additives to increase absorption • Oral - to be more constant • Topical with additives to increase skin permeability • Injectable – to last for a long time • Local – to reduce toxicity
• Not all work for biologics • Need unique solutions designed for biologics
• New “biobetter” technology
• Additives thin drug solution • Enable reduced dose volume • Facilitate rapid home delivery • Use with biosimilars and other biologics
http://drexelmedicine.org/patient-services/rheumatology/services/ http://www.huffingtonpost.com/2013/11/22/h5n1-bird-flu-vaccine-fda_n_4326148.html
Small molecule Biologic
Hospital infusion Injection
Delivery-based solutions are broadly beneficial
Patients Providers Industry Reduced administration costs
Improved access and convenience
Increased compliance
Improved efficacy
No risks from drug development
Faster to market than developing a new drug
Platform technology
Need policy in place to support all players before products reach market
Improved safety